The new health research paradigm in Manitoba : implications for partnerships with the pharmaceutical industry

Simple item page
dc.contributor.authorMcLean, David M. I.en_US
dc.date.accessioned2009-12-08T18:50:16Z
dc.date.available2009-12-08T18:50:16Z
dc.date.issued1996en_US
dc.degree.disciplineBusiness Administrationen_US
dc.degree.levelMaster of Business Administration (M.B.A.)en_US
dc.description.abstractHealth research offers a significant social and economic benefit to Canadians with its outcomes contributing to the betterment of society on a global scale. With fiscal reform occurring at the provincial and federal levels, health research funding has been frozen or reduced over the past few years. In an effort to illuminate the impact of these policies, a clearer understanding of the economic significance of this sector is necessary. An economic model was employed to define the relative economic value of health research, and to thereby substantiate further expenditures in this area. It has been shown that relative to the food processing and communications sectors, and to a pharmaceutical manufacturer in Manitoba, health research has been a robust contributor to GDP and employment in Manitoba. Increasing the value of this sector has therefore been a targetted objective. Surveys of the pharmaceutical industry, the public sector and the academic community have been performed to define obstacles, enablers and critical success factors for enhanced investment by both the public and private sectors. Interviews with a stratified sample of pharmaceutical firms more clearly enunciated decision making criteria for R and D investment. Finally, perspectives on technology commercialization were gained from industry, technology commercialization units throughout North America, and the academic research community in Manitoba. It is apparent that governments should support this activity both through financial resources, and through the development of inter-Ministerial policies that respond to the needs of both health researchers and industry. Manitoba has begun to forge such partnerships in this way, and is, therefore, well-positioned to establish open, communicative, partnerships between the pharmaceutical industry, academia and government.en_US
dc.format.extent[iv], v, 150 leaves :en_US
dc.format.extent7053876 bytes
dc.format.mimetypeapplication/pdf
dc.identifier(Sirsi) AJI-2261en_US
dc.identifier.urihttp://hdl.handle.net/1993/3725
dc.language.isoengen_US
dc.rightsopen accessen_US
dc.rightsThe reproduction of this thesis has been made available by authority of the copyright owner solely for the purpose of private study and research, and may only be reproduced and copied as permitted by copyright laws or with express written authorization from the copyright owner.en_US
dc.titleThe new health research paradigm in Manitoba : implications for partnerships with the pharmaceutical industryen_US
dc.typemaster thesisen_US
local.subject.manitobayesen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
McLean, The New.pdf
Size:
6.73 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
FGS - Electronic Theses and Practica
Manitoba Heritage Theses